logo-loader

Proactive news snapshot: Accesso Technology; Nanobiotix; AdEPT Telecom…

Published: 10:50 13 Jul 2017 EDT

newspapers on a stand

Accesso Technology Group PLC (LON:ACSO) has completed a £58.8m fund raise to pay for its latest expansion, US theme park software specialist The Experience Engine (TE2).

TE2’s software uses heuristic analysis to model customer behaviour at the parks both during their stay and also before and after the visit to predict and give insights into patterns of checking-in, booking ride times and mobile shopping trends.

Based in San Diego, California and Orlando, TE2 was only founded in founded in 2013 but boasts an impressive customer list including Cedar Fair, SeaWorld, Merlin Entertainments, and cruise operator Carnival Corporation. 

Clinical stage drug developer Nanobiotix SA (EPA:NANO) posted revenues of €58,650 in the second quarter of this calendar year.

The company also made good progress with its lead candidate, NBTXR3, in the first six months of 2017, reporting promising data from the recent head/ neck cancer trial on several occasions.

Elsewhere, voice and data communications services provider AdEPT Telecom plc (LON:ADT) has racked up another year of strong growth.

In the year to 31 March, the acquisitive information technology (IT) services achieved its 14th consecutive year of increased underlying earnings before interest, tax, depreciation and amortisation (EBITDA).

Underlying EBITDA rose 27.2% to £7.83mln from £6.15mln the year before on revenue that rose 19.2% to £34.4mln from £28.9mln. The market had been expecting revenue of £34mln.

Thor Mining PLC (LON:THR) saw its shares gain today on news it has completed the acquisition of a 25% stake in US Lithium Pty Limited, a private Australian company with interests in lithium-focused projects in Arizona and New Mexico.

In addition to the US$75,000 purchase price, Thor has also contributed A$50,000 to US Lithium to cover the exploration programme, which is now expected to be fully funded for the next three months. The stake purchase was first announced on June 14.

Providence Resources PLC (LON:PVR) and Lansdowne Oil & Gas Plc (LON:LOGP) have been granted a licence extension for the Barryroe project in Ireland’s Celtic Sea.

The first phase of Standard Exploration Licence 1/11, which hosts Barryroe, has been extended to July 2019, meanwhile, the overall term of the licence now lasts until July 2021.

The extension is subject to the partners completing a work programme, including analysis of new 3D seismic data, and that they provide an assessment of the Jurassic and Triassic potential in the area.

Significantly, it means Providence and Lansdowne have more time to seal a farm-out deal and advance Barryroe into the development and production phases.

Genedrive PLC (LON:GDR) has enjoyed a year of “good progress”, in which it saw revenues rise  as its breakthrough rapid diagnostic for Hepatitis-C moved nearer to European regulatory approval.

The molecular diagnostics specialist submitted its Genedrive HCV ID kit for CE IVD certification back in March and said today it expects to update the market on the outcome of this application in the “near future”.

It wasn’t just a year of operational progress though, Genedrive finished the year in a solid financial position after it saw revenues grow across the board.

For the 12 months to 30 June 2017, the AIM-quoted firm reported group revenues of £5.8mln, comfortably ahead of the £5.1mln it posted last year.

In other news, Savannah Petroleum PLC (LON:SAVP) today confirmed that its reverse takeover target is Seven Energy International Limited, a Nigerian-focused oil and gas company.

The news came in a brief statement noting recent media speculation regarding the identity of the West African focused business with which it has entered into a binding exclusivity agreement.

Savannah said it will “provide further updates in due course and continues to seek to complete the proposed transaction on an accelerated timescale.”

Closer to home, Europa Oil & Gas Holdings Plc (LON:EOG) has confirmed that an appeal is being made against a second refusal of planning permission for the Wressle field in North Lincolnshire.

The junior oil firm noted that project operator Egdon Resources had announced its intention to appeal the most recent decision by the North Lincolnshire Council planning committee.

It also noted Egdon’s guidance that notices advertising Egdon's intention to appeal will be displayed in the local parishes and published in the local paper over the coming week in accordance with planning law.  An appeal will be submitted without delay shortly afterwards.

And Haydale Graphene Industries PLC (LON:HAYD) has appointed David Banks, a senior executive Investment banker who has been the firm’s corporate broker,  as its non-executive chairman with immediate effect.

In a statement, the global nanomaterials group said Bank is replacing John Knowles who, as previously announced, has decided to retire.

Elsewhere, Metal Tiger PLC (LON:MTR) revealed that, since February 8, it has made further cash purchases of shares in Botswana-focused MOD Resources (ASX:MOD), taking its current holding to 91,795,214 shares valued presently at around A$5.69mln (circa £3.408mln).

The AIM-listed natural resources strategic investor also holds 1,541,667 MOD warrants with an exercise price of $A0.06, which expire on 15 April 2019. Michael McNeilly, Metal Tiger’s chief executive officer said:  “We anticipate further market updates in respect of Botswanan exploration progress in the near term.”

And Tlou Energy Limited (LON:TLOU) said it has received confirmation from Botswana's Department of Mines in the Ministry of Mineral Resources, Green Technology and Energy Security that the closing date for the receipt of tender offers for the Ministry's Request for Proposal for the development of up to 100MW of CBM fuelled pilot power plants has been extended to 23 August 2017 from 12 July 2017.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 16 minutes ago